申请人:BioMarin Pharmaceutical Inc.
公开号:EP2660241A2
公开(公告)日:2013-11-06
Provided herein are inhibitors of CYP11B, CYP17, and/or CYP21 enzymes of Formula Z, IX, X, XI, XII, XIII, XIV, XV, XVI, or XVII. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat androgen-dependent diseases, disorders and conditions.
本文提供了式 Z、IX、X、XI、XII、XIII、XIV、XV、XVI 或 XVII 的 CYP11B、CYP17 和/或 CYP21 酶的抑制剂。本文还描述了包括至少一种本文所述化合物的药物组合物,以及本文所述化合物或药物组合物用于治疗雄激素依赖性疾病、失调和病症的用途。